WO2026094004 - COMBINATION TREATMENT FOR MULTIPLE MYELOMA WITH BELANTAMAB MAFODOTIN AND DEXAMETHASONE TOGETHER WITH LENALIDOMIDE, POMALIDOMIDE, BORTEZOMIB, OR CARFILZOMIB, OR WITH LENALIDOMIDE AND BORTEZOMIB
National phase entry is expected:
Publication Number
WO/2026/094004
Publication Date
07.05.2026
International Application No.
PCT/IB2025/061180
International Filing Date
03.11.2025
Title **
[English]
COMBINATION TREATMENT FOR MULTIPLE MYELOMA WITH BELANTAMAB MAFODOTIN AND DEXAMETHASONE TOGETHER WITH LENALIDOMIDE, POMALIDOMIDE, BORTEZOMIB, OR CARFILZOMIB, OR WITH LENALIDOMIDE AND BORTEZOMIB
[French]
TRAITEMENT COMBINÉ POUR UN MYÉLOME MULTIPLE AVEC UNE PROTÉINE DE LIAISON À L'ANTIGÈNE ANTI-BCMA
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
KREMER, Brandon
PAKA, Prani
FERRON-BRADY, Geraldine
Priority Data
63/715,761
04.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5766 | |
| EPO | Filing, Examination, Granting | 90092 | |
| Japan | Filing, Examination, Granting | 4689 | |
| South Korea | Filing, Examination, Granting | 7053 | |
| USA | Filing, Examination, Granting | 24290 |
Total:
131,890
Contact Us
Abstract[English]
Provided herein are methods and compositions for treating multiple myeloma, such as relapsed and/or refractory multiple myeloma and newly-diagnosed multiple myeloma, including transplant-ineligible newly-diagnosed multiple myeloma (TI-NDMM). The methods involve administering to human patients diagnosed with multiple myeloma an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody or anti-BCMA antibody drug conjugate) in combination with lenalidomide, pomalidomide, bortezomib, carfilzomib and/or dexamethasone.[French]
La présente invention concerne des méthodes et des compositions pour traiter un myélome multiple, tel qu'un myélome multiple récidivant et/ou réfractaire et un myélome multiple nouvellement diagnostiqué, comprenant un myélome multiple nouvellement diagnostiqué chez un patient inéligible à une greffe (TI-NDMM). Les méthodes impliquent l'administration à des patients humains chez lesquels on a diagnostiqué un myélome multiple, une protéine de liaison à l'antigène anti-BCMA (par exemple, un anticorps anti-BCMA ou un conjugué anticorps anti-BCMA-médicament) en combinaison avec du lénalidomide, du pomalidomide, du bortézomib, du carfilzomib et/ou de la dexaméthasone.